Navigation Links
InterMune Names Jonathan A. Leff, M.D., as Executive Vice President of Research and Development
Date:2/9/2012

ase 1 to Phase 4 clinical development programs, and has played important roles in successful interactions with regulatory authorities, including NDA submissions, FDA advisory panels, registrations or line extensions of specialty medicines including MabThera®/Rituxan®, Singulair®, Actemra® and Enbrel®.  He also has served as Chief Medical Officer at two biotech companies.  We are delighted to welcome Dr. Leff to InterMune and we look forward to his contributions to the advancement of our scientific and business endeavors."

Jonathan A. Leff, M.D.
Executive Vice President, Research and Development
Dr. Leff is no relation to Mr. Jonathan S. Leff, a Board Director of InterMune.  Prior to joining InterMune February 27, Dr. Leff served since February 2011 as Chief Medical Officer at KaloBios Pharmaceuticals, Inc., a privately held biotechnology company.  He previously served as Vice President and Chief Medical Officer at Halozyme Therapeutics, Inc.  Prior to joining Halozyme in 2009, he was Vice President and Global Head of Inflammation Clinical Development at Roche, where he managed the worldwide clinical development programs for MabThera®/Rituxan®, ocrelizumab, and Actemra®.  From 2002 to 2007, Dr. Leff held various positions at Amgen, including Vice President, North American Medical Affairs, where he led the medical affairs department consisting of 500 professionals, and was responsible for oversight of post-registration studies in multiple therapeutic areas.  From 1994 to 2002, Dr. Leff served at Merck, where he performed Phase 1-4 clinical studies of Singulair®.  From 1984 to 1994, he trained and served in various positions at the University of Colorado, Denver, including director of the Outpatient Pulmonary Clinic.

Dr. Leff holds a bachelor's degree in Chemistry from the University of Pennsylvania, and received his M.D. from the University of Penns
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Reports Preliminary Fourth Quarter 2011 EsbrietĀ® (pirfenidone) Revenue and Other Recent Business Highlights
2. InterMune Appoints Angus C. Russell to Board of Directors
3. InterMune to Release Third Quarter Financial Results on November 3
4. InterMune Announces Launch of EsbrietĀ® (pirfenidone) in Germany
5. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
6. InterMune Receives European Union Approval for EsbrietĀ® (pirfenidone)
7. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Third Quarter 2010 Financial Results
10. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
11. InterMune to Release Second Quarter Financial Results on July 27
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... agreement with Patterson Veterinary Supply. Patterson ... of Abaxis veterinary products throughout the United ...
(Date:10/1/2014)... DIEGO , Oct. 1, 2014  ResMed (NYSE: ... sleep and the first company to design complete sleep apnea ... educate women about the importance of a good night,s sleep. ... will challenge the myth that feeling tired is just part ... understand that sleep is a critical pillar of health, essential ...
(Date:10/1/2014)...   Cypher Genomics, Inc., the genome informatics ... Ravenel as chief technology officer. Ravenel has more ... and a proven track record of designing and architecting ... has been recognized as a top designer and architect ... industry-wide for delivering innovative products that operate at scale ...
Breaking Medicine Technology:Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2
... Romark Laboratories, L.C., a,privately-owned biopharmaceutical company, today ... clinical trial to evaluate the safety and,efficacy of ... in,U.S. patients with chronic hepatitis C genotype 1 ... of care therapy (peginterferon and,ribavirin). The company expects ...
... Urologist Presents OrBIT Study Results Comparing Percutaneous, Tibial Nerve ... ... Meeting, MINNEAPOLIS, May 21 Uroplasty, Inc. (Amex:,UPI), ... proprietary products for the treatment of voiding dysfunction,today highlighted ...
Cached Medicine Technology:Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System 2Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System 3
(Date:10/2/2014)... Steven Reinberg HealthDay Reporter ... to a major highway may raise your risk for high ... 5,000 postmenopausal women, those who lived within 109 yards of ... developing high blood pressure than women living at least half ... this study highlight the importance of our physical environment on ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... and the District of Columbia now have a total of ... that has been infecting children since the summer, U.S. ... virus have died in recent weeks, but it,s not clear ... those deaths, officials said. Health officials are also trying ...
(Date:10/1/2014)... An international team of scientists has shown that more ... treated with existing drugs. , The study found that ... cancers with a genetic mutation that is present in ... JAK inhibitors are currently used, or are in clinical ... and myeloproliferative disorders. , Bowel cancer is the second-most ...
(Date:10/1/2014)... Patients with increased inflammation, including those receiving cytokines ... of depression. For example, a 6-month treatment course ... infection causes depression in approximately 30% of patients. ... as fish oil, have a long list of ... disease and reducing triglyceride levels. These nutritional compounds ...
(Date:10/1/2014)... October 01, 2014 Marriagelifeinsurance.com has ... life insurance for retired couples. , Senior citizens ... financial security for their loved ones. A joint policy ... insured persons pass away. , Life insurance can ... life insurance can even be purchased online, as the ...
Breaking Medicine News(10 mins):Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2
... News) -- Bats and dolphins aren,t the only mammals that ... identify objects and navigate unfamiliar surroundings. Researchers have found ... published online May 25 in PLoS ONE , found ... the faint returning echoes, blind people were able to map ...
... drug that is commonly used to prevent organ transplantation ... finding from UNC scientists was reported in the May ... of surgery, said, " We now have a rationale ... reduces breast cancer growth in humans. Since Tacrolimus is ...
... converging in patient care at a faster pace than ... point-of-care health technologies like telemedicine to medical robots performing ... What,s next? Ask NJIT Distinguished Professor Atam Dhawan, ... Albert Dorman Honors College, chair of the the ...
... , THURSDAY, May 26 (HealthDay News) -- Caffeine, a ... nausea, anxiety and depression. Now, new research reveals that caffeine ... pregnant. By analyzing fallopian tubes in mice, researchers found ... from the ovaries through the fallopian tubes and into the ...
... News)-- Lists of the side effects for prescription medications ... an average of 70 per medication, a new study reports. ... and consumers of potential hazards, but this expansion may have ... health concerns, say the study authors, who argue the information ...
... that has been on the market for decades to treat ... be a possible therapy for vascular diseases, including atherosclerosis and ... Previously, researchers discovered that retinoids commonly used natural ... vascular disease by spurring into action a very particular segment ...
Cached Medicine News:Health News:Blind People May Be Able to Use Echoes to Identify Objects 2Health News:Common transplant drug inhibits breast cancer growth, UNC laboratory study shows 2Health News:5 new hot spots where medicine and technology will converge 2Health News: Caffeine May Interfere With Fertility in Women 2Health News:Lists of Prescription Meds' Side Effects Keep Growing: Study 2Health News:Multitasking meds: Scientists discover how drug for leukemia, psoriasis, may tackle vascular disease 2Health News:Multitasking meds: Scientists discover how drug for leukemia, psoriasis, may tackle vascular disease 3
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
...
Designed for stab incisions...
Medicine Products: